ProQR Therapeutics N.V.
Business
ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing RNA editing therapeutics using its proprietary Axiomer platform, which harnesses endogenous ADAR enzymes to perform precise adenosine-to-inosine edits in RNA. The company's lead program, AX-0810, targets NTCP for cholestatic diseases and is in Phase 1 clinical trials; additional programs address Rett syndrome (AX-2402), metabolic dysfunction-associated steatohepatitis (AX-2911), and cardiovascular disease (AX-1412). ProQR advances wholly-owned pipeline candidates and partners with Eli Lilly (up to ten targets under a global licensing collaboration) and the Rett Syndrome Research Trust.
Summary from 20-F filed 2026-03-12
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-42.18M |
| Total assets | $112.76M |
| Total liabilities | $63.38M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ProQR Therapeutics N.V.'s CIK number?
ProQR Therapeutics N.V.'s SEC CIK number is 0001612940 (1612940). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ProQR Therapeutics N.V.'s SEC filings?
All of ProQR Therapeutics N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.